NCT06948409View on ClinicalTrials.gov

NMBA Reversal and Postoperative Urinary Retention

Not yet recruitingOBSERVATIONAL
Enrollment

70,000

Participants

Timeline

Start Date

May 31, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

August 31, 2026

Conditions
Neuromuscular Blocking AgentsUrinary Retention After ProcedureUrinary Retention PostoperativeNeuromuscular Blockade Reversal AgentNeuromuscular BlockadeCostsAtropineSugammadexGlycopyrrolateNeostigmineAnesthesia
Interventions
DRUG

Choice of reversal agent (sugammadex or neostigmine [with muscaranic antagonist])

The use of sugammadex or neostigmine (in co-administration with muscarinic antagonist) will be compared. The muscarinic antagonists that will be considered are atropine and glycopyrrolate.

Trial Locations (1)

02215

Beth Israel Deaconess Medical Center, Boston

All Listed Sponsors
lead

Beth Israel Deaconess Medical Center

OTHER